Related Experiment Video
Updated: Feb 1, 2026

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2
Yang Wang1, Xiaobing Zhou2, Zhen Wu1
11 National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Centre of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, P.R. China.
Abstract:
Oncolytic virotherapy is a new and safe therapeutic strategy based on the inherent cytotoxicity of oncolytic viruses and their ability to replicate and spread within tumors in a selective manner. In a previous study, a new type of oncolytic herpes simplex virus type 2 (oHSV-2, named OH2) was constructed to treat human cancers. That study demonstrated that OH2 is genetically and biologically stable. Its antitumor activity was maintained, even after passaging the virus for >20 generations. To advance OH2 into a clinical trial, a systematic preclinical safety evaluation was performed, which included: an acute toxicity test of OH2 in BALB/c mice; repeated dose toxicity tests of OH2 in BALB/c mice and cynomolgus monkeys; and biodistribution assays of OH2 in BALB/c mice, tumor-bearing mice, tumor-bearing nude mice, and cynomolgus monkeys. The results of this preclinical safety evaluation of OH2 indicate that OH2 is safe and suitable for clinical trials.
Insights
This study shows that the oncolytic herpes simplex virus type 2 (OH2) is safe for cancer treatment. Preclinical safety evaluations in mice and monkeys indicate OH2 is suitable for human clinical trials.
Area of Science:
- Oncolytic virotherapy
- Cancer therapeutics
- Virology
Background:
- Oncolytic virotherapy utilizes oncolytic viruses for selective tumor replication and cytotoxicity.
- A novel oncolytic herpes simplex virus type 2 (oHSV-2), designated OH2, was previously engineered for human cancer treatment.
- OH2 demonstrated genetic and biological stability, maintaining antitumor activity over multiple passages.
Purpose of the Study:
- To conduct a systematic preclinical safety evaluation of OH2.
- To assess the safety and suitability of OH2 for advancement into clinical trials.
Main Methods:
- Acute toxicity testing in BALB/c mice.
- Repeated dose toxicity studies in BALB/c mice and cynomolgus monkeys.
- Biodistribution assays in various mouse models and cynomolgus monkeys.
Main Results:
- OH2 exhibited no significant toxicity in acute and repeated dose studies.
- Biodistribution studies confirmed the safety profile of OH2 in preclinical models.
- The safety evaluation provides a strong basis for clinical trial initiation.
Conclusions:
- The preclinical safety evaluation indicates that OH2 is safe and well-tolerated.
- OH2 is suitable for further clinical investigation as a cancer therapeutic.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Survey Safety
What are Viruses?
Household Wiring And Electrical Safety
Preclinical Development: Overview
Types of Genetic Transfer Between Organisms

